The
pyrroline-5-carboxylate reductase 1 (PYCR1) plays important roles in
cancers, but its contribution to
adenocarcinoma of the kidney (AK) and the potential mechanism remain to be clarified. In this study, we aimed to demonstrate the relationship between PYCR1
mRNA and AK based on The
Cancer Genome Atlas database.PYCR1
mRNA in AK and normal tissues was compared using Wilcoxon rank sum test. The relationship between PYCR1
mRNA and clinicopathological characters was evaluated using logistic regression. The association between PYCR1
mRNA and survival rate was evaluated using Kaplan-Meier test and Cox regression of univariate and multivariate analysis. Additionally, Gene Set Enrichment Analysis was conducted to annotate the biological function of PYCR1
mRNA.Increased PYCR1
mRNA was found in AK tissues. Increased PYCR1
mRNA was related to high histologic grade, clinical stage, and lymph node and distant
metastasis. Kaplan-Meier survival analysis and univariate analysis showed that AK patients with increased PYCR1
mRNA had worse prognosis than those without. PYCR1
mRNA remained independently associated with overall survival (HR: 1.34; 95% CI: 1.07-1.66; Pā=ā.009) in multivariate analysis. The Gene Set Enrichment Analysis suggested that ribosome,
proteasome, inhibition of p53 signaling pathway,
extracellular matrix receptor interaction, and homologous recombination were differentially enriched in increased PYCR1
mRNA phenotype.Increased PYCR1
mRNA is a potential marker in patients with AK. More importantly, p53 pathway, ribosome,
proteasome,
extracellular matrix receptor interaction, and homologous are differentially enriched in AK patients with increased PYCR1
mRNA.